NCT05730621

A Study to Compare the Effects of Sarpogrelate Sustained Release /Aspirin Combination Therapy Versus Aspirin on Blood Viscosity in the Patients With Peripheral Arterial Disease and Coronary Artery Disease

A Study to Compare the Effects of Sarpogrelate Sustained Release /Aspirin Combination Therapy Versus Aspirin on Blood Viscosity in the Patients With Peripheral Arterial Disease and Coronary Artery Disease; A Prospective, Randomized, Parallel, Open-Label, Single-center, Phase IV Clinical Trial

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 68 (actual)
• Sponsor: Yuhan Corporation · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

This study is to compare the effects of sarpogrelate sustained release /aspirin combination therapy versus aspirin on blood viscosity in the patients with peripheral arterial disease and coronary artery disease

Conditions

• Sarpogrelate
• Blood Viscosity
• Peripheral Arterial Disease
• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	Sarpogrelate Sustained Release/Aspirin	Aspirin 100mg qd and Sarpogrelate Sustained Release 300mg qd for 12 weeks
DRUG	Aspirin	Aspirin 100mg qd for 12 weeks

Timeline

• Start date: 2023-01-11
• Primary completion: 2024-02-28
• Completion: 2024-02-28
• First posted: 2023-02-16
• Last updated: 2025-01-22

Locations

1 site across 1 country: South Korea